You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Moodys
Baxter
AstraZeneca
Medtronic

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,283,380

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,283,380 protect, and when does it expire?

Patent 8,283,380 protects XADAGO and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 8,283,380
Title:Methods for treatment of parkinson's disease
Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s): Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT)
Assignee: Newron Pharmaceuticals S.p.A. (Bresso, IT)
Application Number:10/559,982
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,283,380

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-001 Mar 21, 2017 RX Yes No   Start Trial   Start Trial ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES   Start Trial
Mdd Us XADAGO safinamide mesylate TABLET;ORAL 207145-002 Mar 21, 2017 RX Yes Yes   Start Trial   Start Trial ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,283,380

PCT Information
PCT FiledApril 08, 2004PCT Application Number:PCT/IB2004/001408
PCT Publication Date:October 21, 2004PCT Publication Number: WO2004/089353

International Family Members for US Patent 8,283,380

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 044007   Start Trial
Austria 435012   Start Trial
Australia 2004228782   Start Trial
Brazil PI0409364   Start Trial
Canada 2523188   Start Trial
China 102274517   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
Express Scripts
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.